Eureka Therapeutics Announces Initiation of Phase I/II ARYA-3 Clinical Trial of GPC3 Targeting ARTEMIS^® T Cell Therapy in Liver Cancer

Eureka Therapeutics, Inc. announced the initiation of a Phase I/II clinical trial of ECT204, a GPC3 targeting ARTEMIS^® T-cell therapy for the treatment of hepatocellular carcinoma, the predominant type of liver cancer.